Global Rapid-dissolving Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rapid-dissolving Tablets Market Research Report 2024
Rapid-dissolving Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
According to Mr Accuracy reports new survey, global Rapid-dissolving Tablets market is projected to reach US$ 33020 million in 2029, increasing from US$ 15320 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rapid-dissolving Tablets market research.
The orodispersible tablets market is driven by the increasing demand for patient-friendly and convenient drug delivery systems and the growing focus on improving medication adherence. Orodispersible tablets, also known as orally disintegrating tablets or melt-in-mouth tablets, are designed to dissolve rapidly in the mouth without the need for water, making them easier to swallow, especially for patients who have difficulty swallowing conventional tablets or capsules. The rise in the aging population and the prevalence of chronic diseases contribute to market growth, as these patient populations often face challenges in taking oral medications. Moreover, advancements in formulation technology and taste-masking techniques have improved the palatability and acceptance of orodispersible tablets. However, the market also faces challenges, including the cost of development and manufacturing of specialized formulations and addressing stability and shelf-life concerns. Additionally, obtaining regulatory approvals and ensuring consistent quality and performance can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer a diverse range of orodispersible tablet formulations, collaborate with healthcare providers to address specific patient needs, and address the challenges to meet the increasing demand for patient-friendly and effective drug delivery solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rapid-dissolving Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Rapid-dissolving Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Rapid-dissolving Tablets market is projected to reach US$ 33020 million in 2029, increasing from US$ 15320 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rapid-dissolving Tablets market research.
The orodispersible tablets market is driven by the increasing demand for patient-friendly and convenient drug delivery systems and the growing focus on improving medication adherence. Orodispersible tablets, also known as orally disintegrating tablets or melt-in-mouth tablets, are designed to dissolve rapidly in the mouth without the need for water, making them easier to swallow, especially for patients who have difficulty swallowing conventional tablets or capsules. The rise in the aging population and the prevalence of chronic diseases contribute to market growth, as these patient populations often face challenges in taking oral medications. Moreover, advancements in formulation technology and taste-masking techniques have improved the palatability and acceptance of orodispersible tablets. However, the market also faces challenges, including the cost of development and manufacturing of specialized formulations and addressing stability and shelf-life concerns. Additionally, obtaining regulatory approvals and ensuring consistent quality and performance can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer a diverse range of orodispersible tablet formulations, collaborate with healthcare providers to address specific patient needs, and address the challenges to meet the increasing demand for patient-friendly and effective drug delivery solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rapid-dissolving Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Rapid-dissolving Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices